Literature DB >> 25922720

Effects of bronchoscopic lung volume reduction using transbronchial infusion of autologous blood and thrombin in patients with severe chronic obstructive pulmonary disease.

Yasuyuki Mizumori1, Yoshiro Mochiduki1, Yasuharu Nakahara1, Tetsuji Kawamura1, Shin Sasaki1, Akie Morimoto1, Hiroaki Tsukamoto1.   

Abstract

BACKGROUND: Existing medical treatments have limitations in the management of very severe chronic obstructive pulmonary disease (COPD).
METHODS: We performed bronchoscopic lung volume reduction (BLVR) using transbronchial infusion of autologous blood and thrombin (BLVR with blood) in three patients with very severe COPD whose dyspnea could not be relieved by maximum medical management. Two patients underwent BLVR with blood in the left and right lungs at intervals of a half-year or a year, and one patient underwent this procedure in only the right lung. We assessed the changes in pulmonary function, exercise capacity and quality of life before and after BLVR with blood in a total of five procedures.
RESULTS: The subjects were 58- to 74-year-old males. Their forced expiratory volume in one second (FEV1) percent predicted ranged from 14.8% to 23.4%. BLVR with blood achieved significant improvements as follows (values before → after the procedure, mean ± standard deviation): FEV1 0.45r the L → 0.76r the L (P=0.004), inspiratory capacity 1.50cityo L → 2.05±.05c L (P=0.015), 3-minute walk test 46.8nuteo m → 89.6±34.5 m (P=0.004). Lung function peaked several months after BLVR with blood and returned to nearly the baseline level in 6 months, but exercise capacity was better than that at baseline for at least 12 months. St. George's Respiratory Questionnaire (SGRQ), measured in two patients before and 12 months after the procedure, showed remarkable improvements (-15.6 and -11.9 units).
CONCLUSIONS: BLVR with blood is an effective palliative treatment for very severe COPD.

Entities:  

Keywords:  Bronchoscopy; chronic obstructive pulmonary disease (COPD); emphysema; lung volume reduction; respiratory function tests

Year:  2015        PMID: 25922720      PMCID: PMC4387418          DOI: 10.3978/j.issn.2072-1439.2015.01.10

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  30 in total

1.  Collateral ventilation.

Authors:  E J Cetti; A J Moore; D M Geddes
Journal:  Thorax       Date:  2006-05       Impact factor: 9.139

2.  [Bronchoscopic autologous blood injection for lung volume reduction].

Authors:  Hideo Kobayashi; Soichiro Kanoh
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2009-09

3.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock; P Littlejohns
Journal:  Am Rev Respir Dis       Date:  1992-06

4.  Predicting atelectasis by assessment of collateral ventilation prior to endobronchial lung volume reduction: a feasibility study.

Authors:  D Gompelmann; R Eberhardt; G Michaud; A Ernst; F J F Herth
Journal:  Respiration       Date:  2010-07-21       Impact factor: 3.580

5.  Collateral ventilation and gas exchange in emphysema.

Authors:  N W Morrell; B K Wignall; T Biggs; W A Seed
Journal:  Am J Respir Crit Care Med       Date:  1994-09       Impact factor: 21.405

6.  A multicenter pilot study of a bronchial valve for the treatment of severe emphysema.

Authors:  D H Sterman; A C Mehta; D E Wood; P N Mathur; R J McKenna; D E Ost; J D Truwit; P Diaz; M M Wahidi; R Cerfolio; R Maxfield; A I Musani; T Gildea; F Sheski; M Machuzak; A R Haas; H X Gonzalez; S C Springmeyer
Journal:  Respiration       Date:  2009-11-17       Impact factor: 3.580

7.  Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial.

Authors:  Pallav L Shah; Zaid Zoumot; Suveer Singh; Stephen R Bicknell; Ewen T Ross; John Quiring; Nicholas S Hopkinson; Samuel V Kemp
Journal:  Lancet Respir Med       Date:  2013-04-23       Impact factor: 30.700

8.  Bronchoscopic blood injection reducing lung volume in lymphangioleiomyomatosis.

Authors:  Soichiro Kanoh; Hideo Kobayashi; Kazuo Motoyoshi
Journal:  Ann Thorac Surg       Date:  2009-04       Impact factor: 4.330

9.  Clinical application of airway bypass with paclitaxel-eluting stents: early results.

Authors:  Paulo F G Cardoso; Gregory I Snell; Peter Hopkins; Gerhard W Sybrecht; Georgios Stamatis; Alan W Ng; Philip Eng
Journal:  J Thorac Cardiovasc Surg       Date:  2007-08-20       Impact factor: 5.209

10.  Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction.

Authors:  Charlie Strange; Felix J F Herth; Kevin L Kovitz; Geoffrey McLennan; Armin Ernst; Jonathan Goldin; Marc Noppen; Gerard J Criner; Frank C Sciurba
Journal:  BMC Pulm Med       Date:  2007-07-03       Impact factor: 3.317

View more
  4 in total

1.  Low cost biological lung volume reduction therapy for advanced emphysema.

Authors:  Mostafa Bakeer; Taha Taha Abdelgawad; Raed El-Metwaly; Ahmed El-Morsi; Mohammad Khairy El-Badrawy; Solafa El-Sharawy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-08-03

Review 2.  Immunomodulatory Effects of Hydrolyzed Seawater Pearl Tablet (HSPT) on Th1/Th2 Functionality in a Mice Model of Chronic Obstructive Pulmonary Disease (COPD) Induced by Cigarette Smoke.

Authors:  Zhenxing Chen; Qiangqiang Yan; Zhongmin Zhang; Taijin Lan; Peng Liu; Siyin Han; Yong Lin; Jiang Lin
Journal:  Evid Based Complement Alternat Med       Date:  2020-11-18       Impact factor: 2.629

Review 3.  Narrative review of current COPD status in Japan.

Authors:  Naoya Tanabe; Susumu Sato
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

Review 4.  Update on Nonsurgical Lung Volume Reduction Procedures.

Authors:  J Alberto Neder; Denis E O'Donnell
Journal:  Can Respir J       Date:  2016-05-17       Impact factor: 2.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.